Navigation Links
Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
Date:7/14/2009

NEW YORK, July 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 1 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for recurrent solid tumors in pediatric patients. This Phase 1 study is now open for enrollment at Memorial Sloan-Kettering Cancer Center in New York City. Oren Becher, MD, Instructor, Department of Pediatrics, in coordination with Eric Holland, MD, PhD, Director of the Brain Tumor group at Memorial Sloan-Kettering Cancer Center, will act as the study's Principal Investigator. The study announced today is being fully funded by an external grant provided by a private organization.

KRX-0401 is a novel, oral, anticancer agent that modulates Akt and several other important signal transduction pathways. Keryx is currently in the process of finalizing late-stage protocols for Perifosine in the treatment of Multiple Myeloma and Metastatic Colon Cancer.

STUDY RATIONALE:

Activation of the PI3K/AKT pathway has been associated with poor prognosis, or proliferation, in several pediatric tumors such as neuroblastoma, glioblastoma, rhabdomyosarcoma, and medulloblastoma. Perifosine's inhibition of this and other pathways, as well as its ability to cross the blood-brain barrier has generated much interest in exploring its potential activity in the treatment of patients with advanced brain tumors. In vitro and in vivo data presented at AACR 2009 by investigators from the National Cancer Institute demonstrated that single agent perifosine not only induced tumor regression and delayed tumor growth, but that perifosine also improved the survival of mice bearing neuroblastoma tumors. Moreover, in a Phase 2 study conducted at Memorial Sloan-Kettering Cancer Center, perifosine induced responses and delayed disease
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... HYDERABAD, India , July 31, 2015 /PRNewswire/ ... Billing and CRM solutions for video, data and cloud ... (PoC) with a leading pharma giant for Internet ... managing different IoT applications offered on subscription model. ... Pharma giant is striving for business ...
(Date:7/30/2015)... 30, 2015  ResMed (NYSE: RMD ... definitive agreement to acquire Curative Medical, a ... sleep-disordered breathing medical devices and accessories. ... with ResMed,s global leadership in sleep and respiratory medicine, ... China suffering from sleep-disordered breathing ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Void in the Local Treatment of Oral Candidiasis in Immunosuppressed ... PLAINSBORO, N.J., Dec. 5 RHEI Pharmaceuticals, Inc. today announced ... antifungal with low dose miconazole in a patented mucoadhesive system, ... last clinical trial conducted for submission of the New Drug ...
... PARK, Calif., Dec. 4 Long-term data published ... Vale Area (MVA),after repair with the MitraClip(R) system ... clinically significant mitral stenosis. Additionally,with two years of ... system required surgery for mitral stenosis. At 12 ...
Cached Medicine Technology:RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport ... was given that honor by the National Retail Federation, the largest retail trade association ... one of three Maine business owners to be named as such. According to the ...
(Date:8/1/2015)... NY (PRWEB) , ... August 01, 2015 , ... On ... cyberespionage group , who are thought to have been behind the attack on Anthem ... topics covered were zero day exploits, watering hole attacks and spear phishing campaigns. ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers allows users to clarify, edit and delete any message including ones already ...
(Date:7/31/2015)... Vegas, NV (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable ... Vegas at the MGM Grand Garden Arena. Fans of every genre of music will ... Friday, September 18th, the first day of the festival, the following artists will perform: ...
(Date:7/31/2015)... ... 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in Santa ... year is the Super Bowl. In the two weeks that separate the conference championships and ... The 2016 Super Bowl game will mark the 50th time it has been held and ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2
... IRVINE, Calif., Jan. 12 Alsius Corporation,(Nasdaq: ... temperature management,(IVTM(TM)) therapies for critically ill patients, today ... December 31, 2008 revenue. , ... 40 percent to an expected,quarterly record of approximately ...
... ,Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... announced today that they have entered into Settlement ... to Warner Chilcott,s,oral contraceptive products, Loestrin(R) 24 and ... entered into a Co-Promotion Agreement relating,to Warner Chilcott,s ...
... Thermage, Inc.,(Nasdaq: THRM ) announced that effective ... At the open of the NASDAQ exchange this morning,Solta Medical, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090112/AQM049LOGO ) , ... are a great start to the New Year and,a key ...
... Amistaff Healthcare Technology will be holding a developers summit for ... software platform. , ... (Vocus) January ... is changing not just the technology landscape but also the ...
... tough economic times companies can employ comparative effectiveness research tools ... promotion, and health & welfare benefits corporate spending. , ... ... -- The use of comparative effectiveness data addresses large and ...
... 500,000 crashes a year, National Safety Council says , , , ... organization is calling for a nationwide ban on drivers ... there are a few state and local laws banning drivers ... believes it,s time to make it unanimous. , The NSC ...
Cached Medicine News:Health News:Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue 2Health News:Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue 3Health News:Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation 2Health News:Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation 3Health News:Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation 4Health News:Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation 5Health News:Thermage, Inc. Announces Name Change to Solta Medical, Inc. 2Health News:NurseTesting 2.0 Goes to the Clouds and Invites Developers to Summit 2Health News:NurseTesting 2.0 Goes to the Clouds and Invites Developers to Summit 3Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 2Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 3Health News:Nationwide Cell Phone Ban for Drivers Urged 2Health News:Nationwide Cell Phone Ban for Drivers Urged 3Health News:Nationwide Cell Phone Ban for Drivers Urged 4
... Iodine 'Prep' solutions are ... mucous membrane preparation prior ... Povidone Iodine 'Scrub' solutions ... surfactants. Each is effective ...
... BETADINE Solution is ... 10% povidone-iodine. It is ... that kills gram-positive and ... resistant organisms), as well ...
... topical gel contains 10% Povidone Iodine USP, ... As a pre-operative prep, Povidone Iodine Gel ... solutions under the patient, thus reducing the ... also approved as a one step gel ...
... Iodine Prep Solution is appropriate for ... wet soak or spray); disinfecting of ... treatment of lacerations and abrasions. It ... agent in hospital and office procedures, ...
Medicine Products: